Edition:
United States

Evofem Biosciences Inc (EVFM.OQ)

EVFM.OQ on NASDAQ Stock Exchange Capital Market

3.85USD
13 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.85
Open
$3.85
Day's High
$3.85
Day's Low
$3.68
Volume
4,599
Avg. Vol
16,250
52-wk High
$12.84
52-wk Low
$1.80

Summary

Name Age Since Current Position

Saundra Pelletier

2018 Chief Executive Officer

Justin File

2018 Chief Financial Officer

Maria Feldman

52 2016 Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance

Alexander Fitzpatrick

2018 General Counsel, Secretary

Russell Barrans

2018 Chief Commercial Officer

Kelly Culwell

2018 Chief Medical Officer

Kim Kamdar

49 2011 Lead Independent Director

Biographies

Name Description

Saundra Pelletier

Justin File

Maria Feldman

Ms. Maria Feldman is Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance of the Company. Ms. Feldman served as Senior Director of Clinical Research and Operations from March 2014 to February 2016 and consultant to Neothetics from December 2011 to February 2016. Prior to joining, Ms. Feldman was Senior Director of Regulatory Affairs at MediciNova, Inc., from 2004 to 2011. Prior to joining MediciNova, Inc., Ms. Feldman assumed various roles of increasing responsibility within Development Chemistry, Quality and Regulatory Affairs at Isis Pharmaceuticals, Inc., from 1991 to 2004. Ms. Feldman holds a B.A. in Chemistry from St. Olaf College.

Alexander Fitzpatrick

Russell Barrans

Kelly Culwell

Kim Kamdar

Dr. Kim P. Kamdar, Ph.D., serves as Lead Independent Director of Neothetics, Inc. Dr. Kamdar has served as a member of our Board of Directors since April 2011. Dr. Kamdar is a managing member of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005. Prior to joining Domain, Dr. Kamdar served as a Kauffman Fellow with MPM Capital. Prior to joining MPM Capital, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Dr. Kamdar currently serves on the Board of Directors of several private and public companies, including Epic Sciences, Inc., Obalon Therapeutics, Omniome, Inc., ROX Medical, SalveoDx, Sera Prognostics, Singular Genomics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. Dr. Kamdar received her B.A. in genetics and cell biology from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.